- Home
- TPB vs NRIX Comparison
TPB vs NRIX Comparison
Compare TPB & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPB
- NRIX
- Stock Information
- Founded
- TPB 1988
- NRIX 2009
- Country
- TPB United States
- NRIX United States
- Employees
- TPB N/A
- NRIX N/A
- Industry
- TPB Tobacco
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- TPB Consumer Discretionary
- NRIX Health Care
- Exchange
- TPB Nasdaq
- NRIX Nasdaq
- Market Cap
- TPB 1.2B
- NRIX 1.1B
- IPO Year
- TPB 2016
- NRIX 2020
- Fundamental
- Price
- TPB $72.94
- NRIX $9.37
- Analyst Decision
- TPB Strong Buy
- NRIX Strong Buy
- Analyst Count
- TPB 4
- NRIX 17
- Target Price
- TPB $73.75
- NRIX $30.71
- AVG Volume (30 Days)
- TPB 210.8K
- NRIX 895.9K
- Earning Date
- TPB 05-07-2025
- NRIX 07-10-2025
- Dividend Yield
- TPB 0.42%
- NRIX N/A
- EPS Growth
- TPB N/A
- NRIX N/A
- EPS
- TPB N/A
- NRIX N/A
- Revenue
- TPB $384,032,000.00
- NRIX $56,417,000.00
- Revenue This Year
- TPB $17.78
- NRIX $15.43
- Revenue Next Year
- TPB $9.52
- NRIX N/A
- P/E Ratio
- TPB $30.32
- NRIX N/A
- Revenue Growth
- TPB 24.54
- NRIX N/A
- 52 Week Low
- TPB $30.62
- NRIX $8.18
- 52 Week High
- TPB $81.05
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- TPB 63.23
- NRIX 38.14
- Support Level
- TPB $69.50
- NRIX $9.34
- Resistance Level
- TPB $76.61
- NRIX $10.38
- Average True Range (ATR)
- TPB 3.07
- NRIX 0.55
- MACD
- TPB 0.72
- NRIX -0.04
- Stochastic Oscillator
- TPB 61.12
- NRIX 17.96
About TPB Turning Point Brands Inc.
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in three segments namely Zig-Zag products; Stoker's products and NewGen products. The company generates maximum revenue from the Zig-Zag products segment.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.